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Abstract
Background: Systematic reviews are key tools to enable decision making by healthcare providers and policymakers.
Despite the availability of the evidence based Preferred Reporting Items for Systematic reviews and Meta-Analysis
(PRISMA-2009 and PRISMA-P 2015) statements that were developed to improve the transparency and quality of
reporting of systematic reviews, uncertainty on how to deal with pediatric-specific methodological challenges of
systematic reviews impairs decision-making in child health. In this paper, we identify methodological challenges
specific to the design, conduct and reporting of pediatric systematic reviews, and propose a process to address
these challenges.
Discussion: One fundamental decision at the outset of a systematic review is whether to focus on a pediatric
population only, or to include both adult and pediatric populations. Both from the policy and patient care point
of view, the appropriateness of interventions and comparators administered to pre-defined pediatric age subgroup
is critical. Decisions need to be based on the biological plausibility of differences in treatment effects across the
developmental trajectory in children. Synthesis of evidence from different trials is often impaired by the use of
outcomes and measurement instruments that differ between trials and are neither relevant nor validated in the
pediatric population. Other issues specific to pediatric systematic reviews include lack of pediatric-sensitive search
strategies and inconsistent choices of pediatric age subgroups in meta-analyses. In addition to these methodological
issues generic to all pediatric systematic reviews, special considerations are required for reviews of health care
interventions’ safety and efficacy in neonatology, global health, comparative effectiveness interventions and
individual participant data meta-analyses. To date, there is no standard approach available to overcome this
problem. We propose to develop a consensus-based checklist of essential items which researchers should
consider when they are planning (PRISMA-PC-Protocol for Children) or reporting (PRISMA-C-reporting for
Children) a pediatric systematic review.
Summary: Available guidelines including PRISMA do not cover the complexity associated with the conduct
and reporting of systematic reviews in the pediatric population; they require additional and modified standards for
reporting items. Such guidance will facilitate the translation of knowledge from the literature to bedside care and
policy, thereby enhancing delivery of care and improving child health outcomes.
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Background
Historically, children have been underrepresented, and
often excluded, from clinical research [1]. The studies
that have been done in children have shown limited
quality across the hierarchy of research evidence as com-
pared to studies in adults [2]. This leaves pediatric popu-
lations, and end users such as health care providers and
policy makers with a knowledge gap that has led to
treatments based on extrapolations of safety and effect-
iveness from adult data, neglecting the complexities sur-
rounding intervention exposure in children [1, 3, 4], and
leading to under- or over-treatment with potential life-
long consequences. This scarcity of research also affects
evidence synthesis. A survey of the quality and quantity
of evidence on child relevant Cochrane systematic re-
views showed limited number of relevant systematic re-
views in children and even fewer provide representative
information by age-group strata [5].
In modern health care, systematic reviews and meta-
analyses are key tools in decision making by healthcare
providers and policy makers, as they guide patient man-
agement and provide insight towards further research
required. However, the methodological quality of sys-
tematic reviews has been questioned, even of those pub-
lished in high impact factor journal [6, 7]. Concerns
have been raised regarding weaknesses in their design,
conduct, and reporting, which impair their applicability
to practice and policy guidelines [6, 7]. In 2009, the
PRISMA statement was published to provide guidance
to authors, peer reviewers, and journal editors on ele-
ments for optimal reporting of systematic reviews and
meta-analyses of treatment comparisons in order to
maximize the transparency, replicability, and quality of
such studies [8]. In the 2 years following the publication
of PRISMA statement, a modest improvement in com-
pleteness of reporting of systematic reviews and meta-
analyses in sub-specialty journals was reported [9], not
surprisingly primarily in studies published in journals
endorsing the PRISMA statement [10].
For any research project, the reporting stage is too late
to correct errors in design and conduct. The protocol
for a systematic review serves as the foundation of the
study’s conduct and reporting. However, systematic re-
view protocols are seldom published and only 1 in 10
non-Cochrane systematic review mentions working from
a protocol to complete the review [11]. Systematic review
protocols permit readers to determine whether unplanned
decisions, not otherwise documented in a published proto-
col, were introduced including change of primary out-
comes or reporting of statistically significant outcomes
[12]. Unplanned reporting of systematic review results
may lead to biased conclusions and inappropriate de-
cisions by end-users. In contrast, a published or regis-
tered protocol allows a comparison of reported review
methods with the planned methods. Pre-publication
of protocols also avoids unnecessary duplication of efforts
and provides transparency for possible publication bias in
the field [13]. To address these problems, an international
Prospective Register of Ongoing Systematic Reviews
(PROSPERO) was launched in February 2011, and the
PRISMA-P (Preferred Reporting Items for Systematic Re-
views and Meta-Analyses - Protocol) statement providing
an evidence-based guidance on 17 key items to be re-
ported in systematic reviews and meta-analysis protocols
was published in 2015 [14].
Despite these positive developments, a large number
of current pediatric systematic reviews lack clarity in
reporting and therefore offer limited or biased evidence
for recommendations, partly due to the existence of
guidelines that are not specific to child health research.
Evaluations of systematic reviews in some pediatric
subspecialty fields, e.g., oncology [15] and urology [16],
reported low quality. Furthermore, compared to adult
research, a scarcity of high quality evidence in pediatric-
specific research exists for both randomised controlled
trials (RCTs) and systematic reviews [2]. Out of the 4520
systematic reviews that have been registered in PROS-
PERO in February 2015, less than 10% were on the
pediatric population aged 0–18 years. An evaluation of
“child relevant” systematic reviews found that only about
half of the reviews intended to included data from chil-
dren [17]. Unfortunately, where data have been synthe-
sized, results are most often uninformative and unreliable,
due to a high variability in systematic reviews and meta-
analytic methods applied in child health research. Cau-
tious interpretation of inconclusive findings from such
pediatric systematic reviews should be made in order to
assist physicians best communicate the available evidence
with their patients and make the best informed decision
during routine clinical practice. While several of the limi-
tations identified in pediatric systematic reviews might
also reflect limitations of evidence in the original pediatric
RCTs, nevertheless, there are also several areas of im-
provement for the pediatric systematic reviews per se,
which we analytically discuss below.
In this paper, we discuss methodological issues specific
to the design, conduct, analysis and reporting of
pediatric systematic reviews.
Discussion
The ‘PICOSS’ for pediatric specific systematic reviews
A systematic review typically starts with identifying the
PICO (Population, Intervention, Comparator and Out-
comes) for the research question. Two additional ele-
ments need particular attention in pediatric systematic
reviews: the Search Strategy, and any planned Sub-group
analysis. Without a specific and precise research ques-
tion, a review lacks direction and is prone to subjective
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interpretation. Although there is limited empirical ap-
praisal of the quality of systematic reviews for most of
the pediatric subspecialties, as few as 27% of the system-
atic reviews in pediatric urology had a research question
explicitly and properly stated [16]. A well-defined re-
search question is also critical for developing the search
strategy and planning the statistical analysis, in particu-
lar any subgroup analyses. We describe below the conse-
quences unique to each of these issues in pediatric
systematic reviews.
Population
A fundamental decision at the outset of a systematic re-
view is whether to focus on pediatric population only, or
to include both adult and pediatric population. This de-
cision is often based on biological plausibility as children
go through different developmental stages. A survey of
the Cochrane database found that in 35% of the
pediatric relevant systematic reviews, the age criteria of
the intended population in a systematic review was not
specified [17]. Furthermore, 80% of the intended
pediatric systematic reviews actually included pediatric
sub-populations only, while 63% of the intended “mixed
populations” reviews actually included both adult and
pediatric trials and/or mixed trials. However, this might
also reflect the paucity of pediatric RCTs to be included
in a systematic review rather than limitations of the sys-
tematic reviews. Substantial differences exist between
systematic reviews with respect to how infants, children,
adolescents, and adults are defined. This difference may
be due to the variation in age categories used in primary
studies and insufficient attention to the importance of
age groupings for public health relevance [18]. While
PRISMA recommends to explicitly state the patient
population being addressed and their defining characteris-
tics such as disease and the setting of care considered, jus-
tifying the eligible pediatric age range and age group(s)
selected for the systematic review, addressing potential
age related differences in intervention effects are critical
reporting elements in pediatric systematic reviews.
Intervention
It is crucial to consider the growth and developmental
trajectory in describing interventions in pediatric sys-
tematic review. A critical requirement of intervention
description for pediatric systematic review is the justifi-
cation of the suitability of the interventions to the tar-
geted pediatric age group(s), addressing age related
differences in dose, duration, strength, route of adminis-
tration and bioavailability. For example, dosing for vita-
min A supplementation in neonates would be different
from infants 1 to 6 months of age, due to the variation
in pharmacokinetics and pharmacodynamics in different
age strata as well as other contextual factors such as
supplementation of mothers during lactation, birth
weight and timing of vitamin A supplementation, either
within the first 48 to 72 h or later [19]. However, limited
data from primary pediatric studies preclude subgroup
analyses for the different doses of interventions for tar-
geted pediatric age sub-groups, resulting in “false nega-
tive results” (failure to detect true beneficial effects due
to very small subgroups). Such limitations should be
acknowledged in a systematic review. While PRISMA
recommends to explicitly state the interventions or
exposure of interest, justifying an intervention for a
pediatric age range and for specific age subgroups, and
providing a rationale for extrapolation or manipulation
of adult intervention are critical reporting elements in
pediatric systematic reviews.
Comparators
Determination of an appropriate comparator in pediatric
systematic reviews is critical, both from the policy and
patient care point of view. Placebo is a common com-
parator in pediatric systematic reviews as it is in
pediatric clinical trials [20]. Comparators need to be jus-
tified since the “standard of care” may involve an off-
label or unlicensed drug, which often does not have
strong evidence for safety or effectiveness in the
pediatric population [21]. This issue is further complicated
in pediatric systematic review by the fact that placebo re-
sponse rates in drug trials appear to be higher in children
and adolescents in comparison with adults [22, 23], and
consequently, pooled response rates are higher in children
and adolescents than those known for adults with similar
conditions [24]. This higher placebo response in children
also suggests that extrapolating drug efficacy in evidence
synthesised in adults to children may result in underesti-
mating the placebo response and overestimating drug effi-
cacy [24]. Furthermore, all alternate interventions given in
routine clinical practice as a standard of care should be
considered when planning a pediatric systematic review.
While PRISMA recommends to clearly report the com-
parator (control) group, such as standard of care, drug, or
placebo, an explanation for the choice of comparison
group and, if applicable, evidence for the active compara-
tor used (for systematic reviews of RCTs) or “standard of
care” for the pediatric age sub-groups are important
reporting elements in pediatric systematic reviews.
Outcomes
The selection of outcomes a priori should be based on
sound knowledge of the disease trajectory and children’s
growth and development. Relevant short-term and long-
term outcomes may differ for children and adults, and
similar outcomes may be assessed using different meas-
urement tools. While efforts have been made to develop
Core Outcome Sets (COS) for several health conditions,
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many of these COS are not age specific. As health out-
comes in children are different from adults, the method-
ology behind selecting and measuring valid, responsive
and feasible outcomes for pediatric research are key. Core
Outcome Sets for pediatric health conditions are a new
opportunity to attain high research standards [25, 26]. Rec-
ognition that the benefits and harms of treatment for chil-
dren may unfold across subsequent decades of life may
influence the choice of outcomes and study designs to be
included in a systematic review. A recent systematic re-
view suggests paucity and limitations of the evidence in-
vestigating the long-term outcomes of recommended
interventions in children with attention deficit hyperactiv-
ity disorder [27]. Furthermore, use of short and long term
outcomes in pediatric clinical research was often heteroge-
neous and ad hoc, limiting synthesis of evidence in the
pediatric population [28, 29]. This heterogeneous selection
of outcomes presents a challenge when assessing the total-
ity of evidence based on different trials (in the context of
meta-analysis). The synthesis of the accumulated evidence
from different trials into systematic reviews is impaired by
the use of outcomes and outcome measurement instru-
ments that are neither qualified nor validated in pediatric
sub-populations [29], with no standard approach available
to overcome this problem in a systematic review. Out-
comes of interest for a systematic review, but for which no
data could be identified in the primary studies should be
transparently reported in the systematic review as
“remaining knowledge gaps.” A descriptive analysis of
child relevant systematic reviews in the Cochrane database
found that a primary outcome was identified in 72% of
pediatric systematic reviews [5]. However, this number
varied substantially between sub-specialities, from 27% in
injuries to 90% in infectious diseases [5]. A priori identifi-
cation of outcomes is needed to avoid outcome reporting
bias in systematic reviews [12], acknowledging that a priori
primary outcome for the systematic review, might not have
been a primary outcome for the original studies. While
PRISMA recommends to clearly specify the outcomes of
the intervention being assessed, explaining the clinical
relevance of the selected outcomes (benefits and harms)
for the pre-specified pediatric age group(s) and the validity,
feasibility and responsiveness of the outcome measures for
the pre-specified pediatric age group(s) are important
reporting elements in pediatric systematic reviews.
Search strategy
Given the vast amount of research (e.g., currently 24
million citations of biomedical literature in PubMed
alone), clinicians and researchers seeking research stud-
ies for targeted pediatric age subgroups, for example
adolescence or neonates, need to target their literature
searches so that the retrieved information is relevant to
their patient population [30]. Moreover, bibliographic
databases have varying definitions of “child” and other
age-based terms, inconsistent with other databases. Ti-
tles and abstracts of pediatric specific research describe
the age of the study population very inconsistently, if at
all. Pediatric systematic reviews have been reported to
be particularly weak in terms of the comprehensiveness
in their search to identify primary studies [31]. Conse-
quently, search filters have been developed, tested and
validated to capture pediatric studies [30, 32, 33]. A
study by Kastner et. al. determined the retrieval charac-
teristics of age-specific search terms in MEDLINE for
pediatric and neonatal medicine and found that highest
sensitivity and specificity was achieved by a combination
of MESH terms and key words (pediatric medicine - 98
and 81.2% and neonatal medicine - 95.3 and 83.6%, re-
spectively) [30]. While PRISMA recommends to present
the full electronic search strategy, description of any
tested pediatric search filters used in the systematic re-
view including sensitivity and precision of the search fil-
ters for retrieving child health systematic reviews would
improve the appropriateness of search methods used in
the pediatric systematic review.
Statistical (Subgroup) analysis plan
Within the wide age range of 0–18 years, one can expect
differing response to interventions and a wide range of de-
livery methods. Authors should analyse age groups where
there may be important similarities or differences in terms
of physiological and psychosocial development as well as
delivery strategies. However, only 13% of the authors of
pediatric relevant systematic reviews planned to conduct a
subgroup analysis based on age, of which 60% (31/52)
conducted the planned subgroup analysis [17]. Moreover
the use of overlapping pediatric age subgroups has been
reported [18]. In the “pediatric only reviews”, only 23%
provided age sub-group analysis [18], and age categories
used in these analyses varied substantially even for similar
interventions and health conditions [17, 18]. While syn-
thesising data increases statistical power and allows for
more precise effect estimates of treatment comparison, a
meta-analysis covering the whole of the pediatric popula-
tion may be unsuitable when studies are too heteroge-
neous in terms of the pediatric age categories they
include. These important issues will only be able to be
fully assessed when systematic reviews in children use
consistent, clearly reported age sub-groups, which is heav-
ily dependent on the use of consistent age sub-groups in
primary research. While PRISMA recommends to report
any subgroup analyses undertaken, in pediatric systematic
reviews, it is also critical to include description of handling
data from primary studies that include both adult and
pediatric population but without separate subgroup ana-
lysis for pediatric population were dealt in the analysis
(where applicable).
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Special issues in pediatric systematic reviews
Systematic reviews in global child health
The Millennium Development Goals (MDGs), estab-
lished in 2000, committed the global community to
achieve a set of targets by 2015, relative to baseline fig-
ures of 1990. At the core of the MDGs are MDG 4,
which calls for a reduction of under-5 child mortality by
two-thirds, and MDG 5, which calls for a reduction of
maternal mortality by three-quarters and universal ac-
cess to reproductive health [34]. Although some pro-
gress has been achieved, global progress is off-track and
rates of reduction in maternal and child mortality in
many developing countries are much slower than antici-
pated [35, 36]. Therefore, understanding the causes of
child mortality and the effectiveness of the preventive
and treatment interventions has become one of the main
interests of the global health community. Much of the
development and implementation of programs/interven-
tions addressing Maternal and Child Health (MNCH) and
preventable deaths over the last decade has been achieved
by using existing knowledge and evidence [37–42], guided
by systematic reviews and meta-analyses to determine the
most effective interventions and delivery strategies. This
evidence has also been compiled into consensus docu-
ments [43]. However, it is evident that the current status
of global guidance based on systematic reviews of the evi-
dence also highlights major shortcomings in relation to
quality of the evidence; i) due to limited resources, many
of the studies are of limited sample size and insufficiently
powered for key outcomes; ii) included studies do not al-
ways provide disaggregated information of clinical rele-
vance; iii) risk of bias pertaining to source of funding for
included trials was not evaluated in the child health sys-
tematic reviews [44]; iv) diversity of study settings and
contexts that produces enormous confounding and limits
generalizability of findings, requiring routinely explored in
RCTs from different country-settings (more developed vs.
less developed countries [45]; v) mortality is a rare out-
come of an intervention, and the introduction of proxy in-
dicators of mortality creates uncertainty over the true
effects on mortality and causes ambiguous conclusions
[46]. Despite the rigorous nature of the global guidance
process led by the World Health Organization through its
guideline development process [47], in many instances the
quality of the evidence submitted and collated, leaves
much to be desired.
Individual participant data systematic reviews in paediatrics
Traditionally systematic reviews have included meta-
analysed data that have been sourced from published
studies where such data have already been ‘aggregated’
by the researchers and presented in tables, figures and
text. Whilst this is certainly an improvement on merely
selecting published literature in a non-systematic way
and synthesising the results of a collection of studies
through descriptive methods, ‘aggregate data’ meta-
analyses have several important limitations. These in-
clude often not being able to access all data collected in
all trials, data being available only in the published (age)
sub-group categories and the use of different child
health outcome definitions across the included trials.
The use of line-by-line raw data from individual trial
participants, sourced directly from the trialists, can over-
come many of these problems. This is known as individual
participant data, or IPD, meta-analysis. This type of meta-
analysis is used commonly in cancer and cardio-vascular
settings but has only recently been used to address
pediatric questions [48]. IPD meta-analysis is particularly
useful in the commonly seen problem in pediatrics
whereby each trial has used different age cut-points for
presenting sub-group analysis. For example, in trials of
neonatal therapies some will present results sub-grouped
by gestational age </≥ 26 weeks, others </≥ 28 weeks and
others still </≥ 32 weeks. With access to the gestational
age of every infant in every study that is possible with IPD,
consistent age sub-group analyses can be conducted using
the maximal amount of available data [48]. Similarly, the
ability to group participants accurately according to
intervention-level characteristics (e.g. dosage/exposure,
level of background care) enables significantly greater data
utilisation. Another limitation of systematic reviews using
aggregate data is that different trials often use different
definitions of the same outcome (e.g. neonatal chronic
lung disease) making data synthesis problematic. Again,
with access to the various components of an outcome (e.g.
type and duration of respiratory support, additional oxy-
gen challenge tests etc.), common definitions can be
applied across all trials to assess whether or not such
definitional differences impact on the robustness of the
meta-analysis conclusions. For all these reasons, IPD
meta-analysis should be considered more often when
addressing paediatrics questions.
Comparative effectiveness systematic reviews in pediatrics
Pediatric systematic reviews on the comparative effect-
iveness of therapeutic or preventive interventions need
to consider clinically relevant outcomes for each age
subgroup that may be eligible for the intervention that
cover both efficacy and harms. Harms outcomes may in-
clude severe adverse events, discontinuations due to ad-
verse events and mortality, in addition to organ-system
specific adverse events (e.g., renal adverse events) or in-
dividual specific adverse events (e.g. vomiting/diarrhea).
Given that pediatric randomized evidence is often sparse
and inconclusive on its own, evidence on the comparative
effectiveness/safety of interventions based on pediatric
RCTs should be systematically evaluated in the context of
the broader existing evidence, e.g. evidence generated in
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adults [3, 4]. It may be also worthwhile to consider exist-
ing evidence from comparative effectiveness studies using
routinely collected data (e.g. studies based on Electronic
Health Record data or registries, etc. [49, 50]). This may
make pediatric systematic reviews more clinically useful
for policy makers and guideline developers who are asked
to appraise the totality of the available evidence (random-
ized and non-randomized) to make policies and guideline
recommendations. However, due caution is needed in ex-
trapolating from adults to children and in appraising the
validity of observational data for effectiveness purposes.
The agenda of pediatric systematic reviews should also
be broad enough to target all possible interventions (e.g.
medical, surgical and/or non-medical/surgical Interven-
tions) and/or all possible outcomes that could be consid-
ered during routine clinical practice and management of
pediatric patients [51]. Whenever possible, network meta-
analyses should be incorporated in pediatric systematic
reviews to quantitatively appraise the wider agenda of all
available therapeutic options [52].
Finally, the interpretation of the comparative effective-
ness/safety of pediatric interventions should be based on
a priori decision on what would be considered a clinically
significant absolute or relative difference in a pediatric
population. Given the dearth of pediatric evidence, it is
common to have mostly or entirely non-statistically sig-
nificant summary effects in pediatric systematic reviews
and meta-analyses. This should not be considered as pin-
pointing simply that the compared interventions do not
differ. Interpretation of results showing non-statistically
significant differences between compared interventions
should be cautiously done and discussed in the context of
the remaining uncertainty based on the 95% confidence
intervals around the estimated effect-sizes (e.g., when no
statistically significant difference in treatment effect was
found, based on the limited amount of evidence it could
not be excluded that the experimental intervention could
have been up to X% worse or up to Y% better than the
compared intervention).
Systematic reviews in neonates
Neonatal-Perinatal Medicine has a long history of pro-
duction of systematic reviews beginning with the land-
mark book, “Effective Care of the Newborn Infant”,
edited by Sinclair and Bracken [53], to the current
Cochrane Neonatal Review Group, which has published
over 300 systematic reviews in Neonatal-Perinatal Medi-
cine. Neonates represent a unique population. Outcomes,
particularly for preterm infants, are distinct from virtually
every outcome measure in other systematic reviews. This
includes complications of prematurity, such as broncho-
pulmonary dysplasia, intraventricular hemorrhage, necro-
tizing enterocolitis and retinopathy of prematurity. The
neonatal population in particular is prone to significant
developmental problems after being treated for critical ill-
ness in the newborn period. A classic example of this
would be the use of steroids postnatally to prevent or treat
chronic lung disease [54–56]. Short-term outcomes were
extremely beneficial (reduction in oxygen) but long-term
outcomes were particularly concerning (increase in cere-
bral palsy). Without careful analysis of the unique attri-
butes of the at-risk population, as well as outcome
measures that reflect both the short-term and long-term
complications, such reviews lack meaning to the neonatal
community. This has been managed by having specialty
groups, such as the Cochrane Neonatal Review Group,
but clearly standards need to be set worldwide for au-
thors who attempt to do these types of analyses in
this vulnerable population.
Systematic reviews on pediatric topics need special
methodological considerations
Given the methodological differences identified in pediatric
systematic reviews, it is evident that they require additional
and modified standards with regard to design, conduct
and reporting. Differences have been identified in terms
of consideration of the pediatric population and tar-
geted pediatric age group(s), intervention, comparator,
relevant, valid and feasible outcomes in children. Here,
decisions need to be based on the biological plausibility
of differences in treatment effects across the develop-
mental trajectory in children. Further issues specific to
pediatric systematic reviews include lack of pediatric-
sensitive search strategies and inconsistent choices of
pediatric age subgroups in meta-analyses.
The need for pediatric-specific items in reporting
guidelines was also evident in an international consensus
meeting on Standard Protocol Items for Randomized Trials
in Children (SPIRIT-C) and Consolidated Standards of
Reporting Trials in Children (CONSORT-C) in Toronto in
2014 that agreed on 8 and 14 pediatric-specific extension
items, respectively, for the design and conduct (SPIRIT-C)
[57] and reporting (CONSORT-C) [58] of pediatric clinical
trials. In the same meeting of key stakeholders and experts
of pediatric clinical trials, an urgent need of guideline
to conduct pediatric-specific systematic reviews was
highlighted. Therefore, as the need to enhance high qual-
ity primary research in children is more pronounced than
ever, there is for a scientific and ethical obligation for
standardisation of research protocols, research practice,
and reporting standards for pediatric systematic reviews.
In addition to the methodological considerations generic
to all pediatric systematic reviews, special considerations
are required for reviews in neonatology, childhood cancer,
global health, community-based interventions and individ-
ual participant data meta-analyses.
To date, the available reporting guidelines, including
PRISMA (and PRISMA-P), do not adequately cover the
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Table 1 Potential modification and extension items beyond the current PRISMA-P and PRISMA for child-centric systematic reviews
Section/topic # PRISMA-Original Item
Potential modifications* for PRISMA-Children
are bolded
PRISMA-Children Potential extension items
Title
Title 1 Identify the report as a systematic review,
meta-analysis, or both for pediatric population
as a focus of review with age group stated,
if applicable.
Abstract
Structured summary 2 Provide a structured summary including, as
applicable: background; objectives; data sources;
study eligibility criteria, including specifying
targeted pediatric age groups, interventions;
primary and secondary outcomes, study appraisal
and synthesis methods; results; limitations;
conclusions and implications of key findings;
systematic review registration number.
2a. If a systematic review includes both adults and
children, describe a subgroup analysis for the pediatric
population(s) in the methods and results of the abstract
2b. Abstract report broad search strategy related to
pediatric population
2c. Abstract describes applicability or limits of applicability
of results to the pediatric group and sub-group(s)
Introduction
Rationale 3 Describe the rationale for the review in the
context of what is already known.
3a. Describe potential for extrapolation of evidence
from adult data, or why extrapolation is not considered
possible
3b. Describe any hypotheses that relate to particular
pediatric population or pediatric subgroups.
Objectives 4 Provide an explicit statement of questions being
addressed with reference to targeted pediatric
age group(s), interventions, comparisons,
outcomes, and study design (PICOS).
Methods
Protocol and registration 5 Indicate if a review protocol exists, if and where
it can be accessed (e.g., Web address), and, if
available, provide registration information
including registration number.
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length
of follow-up) and report characteristics (e.g.,
years considered, language, publication status)
used as criteria for eligibility, giving rationale.
6a. Participants: Justify the eligible pediatric age range
and age group(s) selected for the systematic review,
addressing potential age related differences in
intervention effects
6b1. Intervention: Justify an intervention for pediatric
age range and age groups
6b2. Provide rationale for extrapolation or manipulation
of adult intervention, if any
6c. Comparison: Explanation for a choice of comparison
group and, if applicable, evidence for active comparator
(for systematic reviews of RCTs) or standard of care for
pediatric population and/or sub-groups
6d1. Outcomes: State all short and long term outcomes
addressed for pediatric population and define them
in detail. State whether they were primary/main or
secondary/additional outcomes
6d2. Outcomes: Explain the clinical relevance of the
selected outcomes (benefits and harms) for the pre-
specified pediatric age group(s)
6d3. Outcomes: Explain the validity, feasibility and
responsiveness of the outcome measures for the pre-
specified pediatric age group(s)
Information sources 7 Describe all information sources (e.g., databases
with dates of coverage, contact with study authors
to identify additional studies) in the search and
date last searched.
Search 8 Present full electronic search strategy for at least
one database, including any limits used, such
that it could be repeated.
8a. Describe the broad search strategy and terms
(including database specific MeSH terms for pediatric
population) used to address the pediatric population
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Table 1 Potential modification and extension items beyond the current PRISMA-P and PRISMA for child-centric systematic reviews
(Continued)
8b. Describe any tested pediatric search filters used in
the systematic review including sensitivity and precision
of the search filters for retrieving child health systematic
reviews
Study selection 9 State the process for selecting studies (i.e.,
screening, eligibility, included in systematic
review, and, if applicable, included in the
meta-analysis).
Data collection process 10 Describe method of data extraction from reports
(e.g., piloted forms, independently, in duplicate)
and any processes for obtaining and confirming
data from investigators.
Data items 11 List and define all variables for which data were
sought (e.g., PICOS, funding sources) and any
assumptions and simplifications made.
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias
of individual studies (including specification of
whether this was done at the study or outcome
level), and how this information is to be used in
any data synthesis.
12a. For each included trial in a systematic review,
indicate (a plan to include) the source of financial
support (such as Government, Academia or Industry),
if any, for the trial(s).
Summary measures 13 State the principal summary measures (e.g., risk
ratio, difference in means).
Synthesis of results 14 Describe the methods of handling data and
combining results of studies, if done, including
measures of consistency (e.g., I2) for each meta-
analysis.
14a. Describe how studies (that include both adult
and pediatric population but) without separate
subgroup analysis for pediatric population were dealt
in the analysis (where applicable)
Risk of bias across studies 15 Specify any assessment of risk of bias that may
affect the cumulative evidence (e.g., publication
bias, selective reporting within studies).
Additional analyses 16 Describe methods of additional analyses (e.g.,
sensitivity or subgroup analyses targeted pediatric
age group(s), meta-regression), if done, indicating
which were pre-specified.
Results
Study selection 17 Give numbers of studies screened, assessed for
eligibility, and included in the review, with reasons
for exclusions at each stage, ideally with a flow
diagram.
Study characteristics 18 For each study, present characteristics for which
data were extracted (e.g., study size, PICOS,
follow-up period) and provide the citations.
18a. Provide sample size of pediatric group and
sub-groups (if applicable) for each study
Risk of bias within studies 19 Present data on risk of bias of each study and,
if available, any outcome level assessment
(see item 12).
Results of individual studies 20 For all outcomes considered (benefits or harms),
present, for each study: (a) simple summary data
for each intervention group (b) effect estimates
and confidence intervals, ideally with a forest plot.
Synthesis of results 21 Present results of each meta-analysis done,
including confidence intervals and measures of
consistency.
21a. Report the numbers of included studies with
pediatric participants and, where applicable, report
the number of events and total pediatric population
on which the result synthesis is based.
21b. Provide a description of the direction and size
of effect in terms meaningful to those who would
put findings into practice in a pediatric population.
Risk of bias across studies 22 Present results of any assessment of risk of bias
across studies (see Item 15).
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complexity associated with systematic reviews in the
pediatric population. These child health unique aspects
of pediatric systematic reviews, some of which have been
addressed in various recent PRISMA extensions (e.g.
IPD [59], Network Meta-Analysis [60] and Equity [61])
and in the SPIRIT-C 2014 Statement [57], are summa-
rized in the Table 1. It has become clear that they play a
decisive role throughout the design, conduct and report-
ing of high quality pediatric systematic reviews.
Future directions
First, we recommend that the current PRISMA state-
ment be used to systematically develop a checklist of es-
sential items which researchers should include when
designing, conducting and reporting pediatric systematic
reviews. Second, it seems time to develop two versions
that could be called PRISMA- PC (Protocol for Chil-
dren) and PRISMA-C (Reporting for Children). The de-
tailed protocol of the planned process for developing
new PRISMA-PC and PRISMA-C statements are
provided elsewhere [62]. These “extensions” of the
current PRISMA statement are aimed to improve the
quality of the information reported in pediatric system-
atic reviews by highlighting the key elements that differ
from adult reviews. The “extended” reporting items
should be underpinned by evidence for their importance.
The impact of this work will be potentially large. Ad-
herence by systematic reviewers to PRISMA and its
“pediatric extensions” will facilitate clarity, completeness,
and transparency of pediatric systematic reviews report-
ing. Explicit descriptions and transparent reporting of
these minimum set of items will best serve the interests
of all stakeholders and will also reveal any deficiencies in
the research if they exist. It is anticipated, given the
focus of knowledge synthesis and the requirement by
journals for relating studies to existing evidence, that
pediatric specific systematic review guidelines would in
turn influence the design, conduct, analysis and report-
ing of primary trials in children. Finally, PRISMA-PC
and PRISMA-C guidance will help facilitate the
Table 1 Potential modification and extension items beyond the current PRISMA-P and PRISMA for child-centric systematic reviews
(Continued)
Additional analysis 23 Give results of additional analyses, if done (e.g.,
sensitivity or subgroup analyses for targeted
pediatric age group(s), meta-regression [see
Item 16]).
Discussion
Summary of evidence 24 Summarize the main findings including the
strength of evidence for each main outcome;
consider their relevance to key groups (e.g.,
healthcare providers, users e.g., children and/
or their parents, and policy makers).
Limitations 25 Discuss limitations at study and outcome level
(e.g., risk of bias), and at review-level (e.g.,
incomplete retrieval of identified research,
reporting bias), including any limitations arising
from pediatric studies that were not available.
Conclusions 26 Provide a general interpretation of the results
in the context of other evidence (e.g., evidence
from adult studies, preclinical studies and studies
based on routinely collected data e.g. Electronic
health Record data or Registry data), and
implications for future research.
26a. Provide extent and limits of applicability of
the synthesised evidence to pediatric population
of interest and describe the evidence and logic
underlying those judgements.
26b. Provide implication for research, practice, or
policy related to pediatric population where relevant
(e.g., types of research needed to address unanswered
question in the pediatric population).
26c. Provide a general interpretation of the results
in the context of other evidence (e.g., evidence from
adult studies, observational studies, and pre-clinical
studies). Provide implications for future research,
practice, or policy related to the targeted pediatric
age group(s).
Funding
Funding 27 Describe sources of funding for the systematic
review and other support (e.g., supply of data);
role of funders for the systematic review.
*modifications text in the original items are bold; extension items are represented in a separate column labelled as PRISMA-Children Potential extension items
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translation of knowledge from the literature to bedside
care, thereby improving child health and reduce the
burden on the healthcare system.
Conclusions
Systematic reviews are key tools to enable decision making
by healthcare providers and policymakers. The Preferred
Reporting Items for Systematic reviews and Meta-Analysis
- PRISMA-2009 and PRISMA-P 2015 - statements were
developed to improve the transparency and quality of
reporting of systematic reviews. The lack of guidance in
these statements for pediatric-specific methodological
features of systematic reviews on child health topics may
impair decision-making in child health. In collaboration
with members of the PRISMA Group, we will develop a
consensus-based checklist of essential items which re-
searchers should include when planning and reporting
pediatric systematic reviews. PRISMA-PC (protocol-chil-
dren) and PRISMA-C (reporting-children) guidance will
help facilitate the translation of knowledge from the litera-
ture to bedside care and policy, thereby improving child
health outcomes and enhancing delivery of care.
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